Testosterone - Generic Drug Details

What are the generic drug sources for testosterone and what is the scope of freedom to operate?

Testosterone is the generic ingredient in twenty-three branded drugs marketed by Abbvie, Alza, Acerus, Besins Hlthcare, Endo Operations, Actavis Labs Ut Inc, Alembic, Amneal, Encube, Lupin, Padagis Israel, Perrigo Israel, Twi Pharms, Xiromed, Upsher Smith Labs, Ani Pharms, Strides Pharma Intl, Dr Reddys, Watson Labs, Eli Lilly And Co, Apotex, Cipla, Lupin Ltd, Auxilium Pharms Llc, Pfizer, Am Regent, Caplin One Labs, Eugia Pharma, Hikma, Hikma Farmaceutica, Padagis Us, Rising, Sun Pharm Inds Ltd, Watson Pharms Inc, Wilshire Pharms Inc, Azurity, Endo Pharms, Nexus, Antares Pharma Inc, Bel Mar, Elkins Sinn, Lilly, Tolmar, Marius, and Verity, and is included in seventy-six NDAs. There are seventy-seven patents protecting this compound and six Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Testosterone has ninety-six patent family members in thirty-three countries.

There are sixty-nine drug master file entries for testosterone. Seventeen suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for testosterone

International Patents:	96
US Patents:	77
Tradenames:	23
Applicants:	45
NDAs:	76
Drug Master File Entries:	69
Finished Product Suppliers / Packagers:	17
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,134
Patent Applications:	7,708
Drug Prices:	Drug price trends for testosterone
Drug Sales Revenues:	Drug sales revenues for testosterone
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for testosterone
What excipients (inactive ingredients) are in testosterone?	testosterone excipients list
DailyMed Link:	testosterone at DailyMed

See drug prices for testosterone

See drug sales revenues for testosterone

Recent Clinical Trials for testosterone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of British Columbia	NA
Azurity Pharmaceuticals	PHASE4
University of Miami	PHASE4

See all testosterone clinical trials

Generic filers with tentative approvals for TESTOSTERONE

Applicant	Application No.	Strength	Dosage Form
		30MG/1.5ML ACTUATION	SOLUTION, METERED;TRANSDERMAL
		750MG/3ML (250MG/ML)	INJECTABLE;INTRAMUSCULAR

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for testosterone

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

Medical Subject Heading (MeSH) Categories for testosterone

Androgens

Anatomical Therapeutic Chemical (ATC) Classes for testosterone

G03BA	3-oxoandrosten (4) derivatives
G03B	ANDROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for TESTOSTERONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AXIRON	Topical Solution	testosterone	30 mg/1.5 mL	022504	1	2013-01-29
FORTESTA	Gel	testosterone	10 mg/actuation	021463	1	2012-08-14
TESTIM	Gel	testosterone	1%	021454	1	2008-08-21

US Patents and Regulatory Information for testosterone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-001	Sep 28, 2018		RX	Yes	Yes			Y
Am Regent	TESTOSTERONE CYPIONATE	testosterone cypionate	INJECTABLE;INJECTION	207742-001	Jun 16, 2017	AO	RX	No	No
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	022309-002	Sep 7, 2012	AB2	RX	Yes	No			Y
Tolmar	JATENZO	testosterone undecanoate	CAPSULE;ORAL	206089-003	Mar 27, 2019		RX	Yes	Yes			Y	Y

Expired US Patents for testosterone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	021015-002	Feb 28, 2000
Besins Hlthcare	ANDROGEL	testosterone	GEL, METERED;TRANSDERMAL	021015-003	Sep 26, 2003
Alza	TESTODERM	testosterone	FILM, EXTENDED RELEASE;TRANSDERMAL	019762-001	Oct 12, 1993

EU/EMA Drug Approvals for testosterone

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for testosterone

Country	Patent Number	Title	Estimated Expiration
South Korea	101342357
Eurasian Patent Organization	019214	СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ ДЕФИЦИТОМ АНДРОГЕНОВ У ВЗРОСЛЫХ МУЖЧИН (METHOD OF TREATMENT OR PREVENTION OF DISEASES CAUSED BY ANDROGEN DEFICIT IN ADULT MEN)
World Intellectual Property Organization (WIPO)	2006128255
Israel	190522

Market Dynamics and Financial Trajectory for Testosterone Drugs

Last updated: February 12, 2026

Testosterone remains a significant segment within the broader hormone therapy market. The drug’s applications span male hypogonadism, hormone replacement therapy (HRT), and off-label uses such as athletic performance or aging-related decline. These factors influence market size, competitive landscape, regulatory environment, and revenue projections.

---

What is the current market size and growth rate for testosterone drugs?

The global testosterone replacement therapy (TRT) market was valued at approximately $2.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5.6% from 2023 to 2030, reaching around $3.8 billion by 2030. Key drivers include aging male populations, increased awareness of hypogonadism, and rising demand for HRT.

Comparison with the broader hormone therapy market: The hormone therapy market itself exceeds $17 billion globally, with testosterone constituting roughly 13%.

---

What are the key factors influencing market growth?

• Aging Population: The male population over 60 accounts for a significant proportion of TRT prescriptions; by 2030, this demographic is expected to grow by 40% globally (United Nations, 2022).

• Changing Prescribing Practices: Physicians increasingly prescribe testosterone for symptomatic hypogonadism, backed by clinical guidelines from organizations like the Endocrine Society.

• Regulatory Environment: Regulatory approvals have become stricter, with agencies emphasizing safety. The FDA has issued warnings regarding testosterone’s cardiovascular risks, impacting prescribing behaviors (FDA, 2015).

• Off-Label Use and Abuse: There's ongoing concern about non-medical use, especially within athletic communities, which influences regulatory and market dynamics.

What are the leading brands and patent statuses?

Major companies active in the testosterone market include:

• AbbVie: Testosterone (Androgel), approved since early 2000s, with multiple formulations including gels, patches, and injectable forms.
• Endo Pharmaceuticals: First to market with testosterone topical gels.
• Novo Nordisk: Focused on injectable testosterone.

Many formulations are off-patent, increasing generic competition. For patent-protected products, exclusivity periods range from 10 to 15 years, typically expiring between 2015-2025.

Recent patent expirations have led to increased generics, reducing average product prices by approximately 30%, pressuring revenues for branded products.

What are the current and projected revenue streams?

Year	Estimated Market Size	Branded TRT Revenue	Generic TRT Revenue	Notes
2022	$2.3 billion	$1.8 billion	$0.5 billion	Branded products dominate; decline after patent expiry.
2025	$2.9 billion	$2.0 billion	$0.9 billion	Increased generics.
2030	$3.8 billion	$2.3 billion	$1.5 billion	Market expansion persists.

Revenue growth driven by increased adoption and demographic expansion.

---

How will regulatory and safety concerns influence financial performance?

Regulatory scrutiny impacts R&D, marketing, and sales. The FDA’s cardiovascular safety warnings led to a 20% decline in prescription volumes in the US from 2014-2017. Future regulations targeting off-label use or abuse potential could further constrain growth.

Safety concerns have also led to increased liability risks, prompting companies to invest significantly in clinical research. This elevates R&D costs but is necessary to maintain or extend patent protections or approval.

What is the R&D pipeline focus?

Companies are developing new formulations with improved delivery—such as long-acting injectables and transdermal patches—to address patient compliance issues. Additionally, biosimilars are entering the field, with at least five candidates in advanced clinical stages.

---

How does competition from biosimilars and alternative therapies impact prospects?

• Biosimilars: They threaten branded products post-patent expiry, potentially reducing prices by up to 50%.
• Alternative therapies: Emerging options like selective androgen receptor modulators (SARMs) aim to replicate testosterone's effects with fewer safety concerns, potentially disrupting traditional TRT markets.

---

What are the key risks and opportunities?

Risks:

• Regulatory actions limiting off-label use.
• Public perception issues stemming from safety warnings.
• Patent cliffs increasing generic competition.
• Rising R&D costs driven by safety requirements.

Opportunities:

• Development of safer, more targeted testosterone formulations.
• Expansion into markets with growing healthcare infrastructure (e.g., Asia-Pacific).
• Strategic partnerships and licensing deals for biosimilars and novel compounds.

---

Key Takeaways

1. The testosterone market is valued at approximately $2.3 billion (2022), expected to grow at a CAGR of 5.6% through 2030.
2. Aging populations and increasing awareness drive demand, but regulatory safety warnings and patent expiries dampen growth and lead to price competition.
3. Leading brands include AbbVie and Endo Pharmaceuticals; generic competition intensifies post-patent expiry, affecting revenues.
4. Innovation focuses on long-acting formulations and biosimilars, with regulatory hurdles influencing development timelines.
5. Market risks include safety concerns and regulatory restrictions, yet opportunities exist in new delivery methods and expanding geographies.

---

FAQs

1. How does patent expiry impact testosterone drug revenues?
Patent expiry allows generic competitors to enter the market, reducing prices and eroding revenue from branded products. Revenues often decline by 30-50% within two years after patent expiration.

2. Are biosimilars likely to replace branded testosterone products?
Biosimilars will increase competition and likely reduce prices for existing formulations. However, fully substituting branded products depends on regulatory approval and physician acceptance.

3. How significant are safety concerns in shaping market growth?
Safety warnings from agencies like the FDA about cardiovascular risks have prompted cautious prescribing. These concerns can limit market expansion but also foster innovation for safer alternatives.

4. What market segments are growing fastest within testosterone therapies?
Long-acting injectable formulations and transdermal patches are experiencing the fastest growth due to improved compliance and convenience.

5. What regions hold the greatest growth potential for testosterone drugs?
Asia-Pacific and Latin America show high growth potential due to increasing healthcare access, rising awareness, and aging demographics.

---

Citations

1. Allied Market Research. (2022). Testosterone Replacement Therapy Market.
2. United Nations. (2022). World Population Ageing.
3. U.S. Food and Drug Administration. (2015). FDA Safety Announcement on Testosterone Products.